|Articles|December 22, 2021
Daily Medication Pearl: Crestor (Rosuvastatin)
Author(s)Saro Arakelians, PharmD
Crestor is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia.
Advertisement
Medication Pearl of the Day: Crestor (Rosuvastatin)
Indication: Crestor is used as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C for patients with primary hyperlipidemia and mixed dyslipidemia.
Insight:
- Dosing time: Crestor can be taken with or without food at any time of day.
- Dose range: Dosing for Crestor can range from 5 to 40 mg once daily. The 40 mg dose should be used only for patients not reaching their LDL-C goal with 20 mg.
- Dosage forms: Tablets for Crestor come in dosage forms of 5 mg, 10 mg, 20 mg, and 40 mg.
- Adverse events (AEs): The most frequent AEs (rate ≥ 2%) are headache, myalgia, abdominal pain, asthenia, and nausea.
- Mechanism of action: Crestor is a selective and competitive inhibitor of HMG-CoA reductase, which is the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, which is a precursor of cholesterol.
- Manufacturer: AstraZeneca
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
2
Effectively Managing Immunizations in the Long-Term Care Setting
3
Creating a Culture of Quality in Fast-Melt Tablet Development
4
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
5